Inhibitor Therapeutics Inc (INTI) Stock Price & News

All values in USD	2025-ж. сен.	2025-ж. дек.	2026-ж. мар.	2026-ж. июн.
Revenue	-	-	-	-
Cost of goods sold	-	-	-	-
Cost of revenue	-	-	-	-
Research and development expenses	377,79 миң	757,25 миң	340,56 миң	223,56 миң
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	363,43 миң	557,87 миң	355,07 миң	395,03 миң
Operating expense	741,22 миң	1,32 млн	695,63 миң	618,60 миң
Total operating expenses	741,22 миң	1,32 млн	695,63 миң	618,60 миң
Operating income	-741,22 миң	-1,32 млн	-695,63 миң	-618,60 миң
Other non operating income	-	-	-	-
EBT including unusual items	-712,18 миң	-1,30 млн	-686,42 миң	-613,93 миң
EBT excluding unusual items	-712,18 миң	-1,30 млн	-686,42 миң	-613,93 миң
Income tax expense	-	-	-	-
Effective tax rate	-	-	-	-
Other operating expenses	-	-	-	-
Net income	-712,18 миң	-1,30 млн	-686,42 миң	-613,93 миң
Net profit margin	-	-	-	-
Earnings per share	-	-	-	-
Interest and investment income	29,03 миң	19,75 миң	9,21 миң	4,66 миң
Interest expense	-	-	-	-
Net interest expenses	29,03 миң	19,75 миң	9,21 миң	4,66 миң
Depreciation and amortization charges	-	-	-	-
EBITDA	-	-	-	-
Gain or loss from assets sale	-	-	-	-

Finance